Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · New England Journal of Medicine · 5,300 citations
https://doi.org/10.1056/nejmoa1709684
C
C. Lance Cowey
Texas Oncology(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
111
Papers
21.8K
Citations
32
h-index
56
i10-index
C. Lance Cowey is an academic researcher from Texas Oncology. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Melanoma and MAPK Pathways. The author has an h-index of 32, co-authored 95 publications.
ORCID: 0000-0001-8597-8486Papers by this author
worksAdjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
2017 · New England Journal of Medicine · 2,174 citations
https://doi.org/10.1056/nejmoa1709030
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
2024 · New England Journal of Medicine · 378 citations
https://doi.org/10.1056/nejmoa2407417
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
2022 · Journal of Clinical Oncology · 124 citations
https://doi.org/10.1200/jco.22.00221
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
2009 · Oncogene · 41 citations
https://doi.org/10.1038/onc.2009.12
LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma
2024 · Annals of Oncology · 3 citations
https://doi.org/10.1016/j.annonc.2024.08.2284
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat